Drug Database
AR

aripiprazole (Abilify Maintena / Lu AF41155 / aripiprazole ERIS)

✓ Approved

Otsuka Holdings Co., Ltd. · DRD2 · Small Molecule

What is aripiprazole?

aripiprazole is a small molecule developed by Otsuka Holdings Co., Ltd.. It is approved for therapeutic indications via injectable (others) or intramuscular (im) injection.

Drug Profile

Brand NamesAbilify Maintena, Lu AF41155, aripiprazole ERIS
CompanyOtsuka Holdings Co., Ltd.
Drug ClassSmall Molecule
Molecular TargetDRD2, HTR1A, HTR2A
RouteInjectable (Others), Intramuscular (IM) Injection
StatusApproved

Mechanism of Action

Molecular Targets

aripiprazole acts on 3 molecular targets:

DRD2dopamine receptor D2 (D2DR, D2R)
HTR1A5-hydroxytryptamine receptor 1A (PFMCD, 5-HT1A)
HTR2A5-hydroxytryptamine receptor 2A (5-HT2A, HTR2)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

aripiprazole is developed for 2 unique indications across 1 therapeutic area.

Therapeutic AreaConditionPhase
Psychiatric disordersSchizophrenia✓ Approved
Psychiatric disordersBipolar disorder✓ Approved

Related Research Articles

PubMedMicrobiome2026-07-17

Invertebrates gut viromes mediate microbial adaptation to pharmaceutical diversity under warming.

Wang Ya-Ning YN, Zheng Jin-Ting JT, Chen Xue-Peng XP, Shen Luo-Qin LQ et al.

Pharmaceutical pollution is an emerging environmental concern that can disrupt microbial communities and ecological processes, while climate warming adds further stress with broad ecological consequences. Soil invertebrates such as collembolans harbor gut microbiomes essential for host health and ecosystem stability, yet the responses of these communities-particularly viral communities-to combined pharmaceutical and warming pressures remain unclear. Here, we used controlled microcosm experiments with Folsomia candida to investigate how pharmaceutical diversity and fluctuating warming jointly shape gut microbiomes through bacteria-virus interactions. Pharmaceutical diversity significantly reduced the alpha diversity of gut viral communities in F. candida, an effect not observed in surrounding soils. Diurnal warming increased the proportion of lysogenic phages and enhanced auxiliary metabolic genes (AMGs) such as ACADM and nrdA. Functional validation in Escherichia coli BL21 confirmed that these genes mitigate oxidative stress and improve host thermal tolerance. In contrast, diverse pharmaceuticals increased the proportion of lytic phages, likely driving nutrient turnover through a "kill-the-winner" dynamic that stimulated bacterial taxa involved in pharmaceutical degradation. Moreover, warming amplified the disruption of gut bacterial communities caused by pharmaceutical diversity and strengthened bacteria-virus co-occurrence networks. Our findings reveal that gut viruses act as pivotal regulators of microbial adaptation under concurrent chemical and climate stressors. By mediating host resilience and microbial dynamics, the gut virome provides mechanistic insights into ecosystem stability, and may also serve as an early indicator of combined pharmaceutical and warming stress in soil invertebrate systems, underscoring the need to integrate viral-microbial interactions into One Health framework for environmental risk assessment. Video Abstract.

PubMedBiomacromolecules2026-07-17

Nanodisc-Forming Polymers as TLR7/8 Agonist-Conjugated Immunotherapy Agents.

Borthwick Neil J NJ, Pugh Ciara F CF, Johansen Kristoffer H KH, Maikawa Caitlin L CL et al.

Amphiphilic polymers can solubilize membrane proteins in what is coined native lipid nanodiscs, although their potential as drug delivery platforms is mostly unexplored. Herein, we covalently attached a Toll-like receptor 7/8 agonist to poly(acrylic acid-co-styrene) to generate a multimodal cancer immunotherapy platform (AASTY-TLR7/8ag.) that acts as a loco-regional Toll-like receptor 7/8 agonist depot and as a nanodisc-driven in situ immunization platform. We show that AASTY-TLR7/8ag. therapy translates into tumor growth inhibition in CT26 and other murine cancer models, with the induction of immune memory, synergy with anti-PD-1, and limited on-target/off-tumor toxicity. By formulating nanodiscs from cancer cell membranes in vitro, we also observed that subcutaneous injection in mice leads to rapid distribution in lymph nodes and immune activation of dendritic cells, highlighting the broader potential of AASTY-TLR7/8ag. as a tool for immunization.

PubMedAnalytical methods : advancing methods and applications2026-07-17

Exploiting von Pechmann coumarin derivatization for spectrofluorimetric determination of formoterol in pharmaceutical samples with application to content uniformity testing.

Derayea Sayed M SM, Badry Sara I SI, Nagi Dalia M DM, Oraby Mohamed M

A sensitive spectrofluorimetric technique exhibiting acceptable selectivity was established for the quantification of formoterol (FMT) via the von Pechmann condensation reaction, leading to the formation of intensely fluorescent coumarin derivatives. In this reaction, FMT interacts with ethyl acetoacetate in the presence of concentrated sulfuric acid, producing a fluorescent product. The emitted fluorescence was recorded at 445 nm following excitation at 361 nm. Experimental parameters influencing the reaction were carefully optimized to achieve maximum fluorescence response and method stability. The proposed method exhibited excellent linearity across the concentration range of 20-500 ng mL-1, with a correlation coefficient (r) of 0.9998. The limits of detection (LOD) and quantification (LOQ) were found to be 4 ng mL-1 and 12 ng mL-1, respectively. Acceptable selectivity was demonstrated under the studied formulation conditions, as no significant interference was observed from commonly used pharmaceutical excipients, including lactose monohydrate, magnesium stearate, gelatin, titanium dioxide and placebo. A reaction pathway based on the reported von Pechmann condensation was proposed, and the method was validated in accordance with ICH guidelines. The applicability of the method was successfully demonstrated for the determination of FMT in pharmaceutical dosage forms, including content uniformity testing, showing satisfactory recovery results. Finally, the environmental impact of the method was assessed using various greenness evaluation tools, indicating a favorable greenness profile and practical applicability.

PubMedBehavioural brain research2026-07-17

Comparison of the effects of atypical antipsychotics on decreased libido in zebrafish and their mechanisms.

Shinokawa Kanon K, Hattori Saki S, Miyauchi Masatoshi M, Noguchi Nobuhiko N et al.

Antipsychotic-induced decreased libido is a common clinical concern, yet drug-specific differences and their underlying neurobiological mechanisms remain poorly understood. We chronically exposed adult male zebrafish to risperidone (RIS), olanzapine (OLZ), quetiapine (QTP), or aripiprazole (ARP) to evaluate their effects on courtship behavior. Brain and testicular transcripts related to the hypothalamic-pituitary-gonadal (HPG) axis, kisspeptin, and monoamine receptors, along with systemic 11-ketotestosterone (11-KT) concentrations, were subsequently analyzed. RIS significantly decreased courtship duration, followed by a downward trend in the OLZ group, whereas QTP and ARP showed no detrimental effects. At the molecular level, RIS significantly reduced brain kiss2 and upregulated prl1 transcript levels. Conversely, the ARP group demonstrated a local transcriptional upregulation of neurosteroidogenic enzymes (cyp11c1 and hsd11b2) and downregulation of the inhibitory gnihr1 pathway in the brain, which may help preserve reproductive drive. Furthermore, RIS and OLZ groups showed significant transcriptional upregulation of central dopamine and serotonin receptors, reflecting marked monoaminergic alterations. These findings suggest that QTP and ARP have minimal impacts on libido, while RIS and OLZ carry a higher risk. This differential susceptibility is likely mediated by a complex interplay of kiss2 downregulation, prolactin elevation, altered local neurosteroidogenesis, and monoamine receptor transcript adjustments, rather than a uniform suppression of the peripheral HPG axis.

PubMedSocial science & medicine (1982)2026-07-17

Diagnostic infrastructuring: Biomarkers, pharmaceutical marketing and governance in Taiwan.

Wang Yeh-Han YH, Kuo Wen-Hua WH

This ethnographic study examines the role of pharmaceutical companies in the era of precision medicine. Focusing on PD-L1 biomarker testing for cancer immunotherapy under Taiwan's National Health Insurance reimbursement policy, we trace how these diagnostics are introduced, adopted, and governed within the policy regime that frames therapeutic access. We propose the concept of "diagnostic infrastructuring" to describe how corporate entities act as "infrastructural architects," actively remodeling material platforms and clinical practices to facilitate the routinization of biomarker tests. Extending Sergio Sismondo's discourse on "assemblage marketing," this study reveals a shift toward material and practice governance. In this model, firms mobilize technical objects, standardize practices, and negotiate interpretive discretion and leniency to align with rigid policy frameworks, thereby bridging infrastructural gaps. By governing diagnostic routines, companies embed commercial interests directly into the clinical and reimbursement infrastructures of precision medicine. Ultimately, this industry-driven infrastructuring illuminates an evolving political economy where the capacity to deliver precision medicine is contingent upon the power to configure biomarker diagnostic practice.

PubMedJournal of the American Heart Association2026-07-17

Sodium-Containing Pharmaceutical Products as Contributors to Cardiovascular Risk.

White William B WB, Kovacs Richard J RJ

Restricting sodium intake has been identified as one of the most cost-effective measures to improve public health. The substantial improvements in blood pressure and cardiovascular outcomes observed after dietary sodium restriction in clinical trials and observational studies provide evidence-based support for national strategies that recommend limits on daily sodium consumption. Although dietary sources of sodium account for most of an individual's intake, the sodium content of pharmaceutical products can also contribute to excess sodium intake, thereby increasing cardiovascular risk. Sodium is included in oral medications as an active ingredient (or as a cation for an active ingredient) or to enhance solubility. The sodium content of certain medications can exceed the daily recommended maximal sodium intake if higher doses are administered. In this contemporary review, we describe the basis of cardiovascular risk with increased sodium intake as it pertains to the clinical relevance of medications with a high-sodium content that are associated with increases in blood pressure, development of hypertension, and adverse cardiovascular outcomes. Improvements in approaches to sodium content labeling and prescriber education are warranted to ensure that patients receive appropriate therapeutic options.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about aripiprazole